Xu Ting, Guo Pu, Pi Chao, He Yingmeng, Yang Hongru, Hou Yi, Feng Xianhu, Jiang Qingsheng, Wei Yumeng, Zhao Ling
Department of Pharmaceutics, School of Pharmacy, Southwest Medical University, No. 319, Zhongshan Rd Sanduan, Jiangyang District,Luzhou, Sichuan, 646000, P.R.China.
The Affiliated Hospital, Southwest Medical University, No.25, Taiping Street, Luzhou, Sichuan, 646000, China.
J Cancer. 2020 Apr 6;11(13):3955-3964. doi: 10.7150/jca.41783. eCollection 2020.
Curcumin (CU) has shown broad anti-cancer effects. 5-fluorouracil (5-FU) has been a conventional chemotherapeutic agent for hepatocellular carcinoma. Unfortunately, the nonspecific cytotoxicity and multidrug resistance caused by long-term use limited the clinical efficacy of 5-FU. This study was aimed to investigate whether the combination of CU and 5-FU could generate synergistic effect in inhibiting the human hepatocellular carcinoma. The results of cytotoxicity test showed that compared with applying single drugs, the combination of CU and 5-FU (1:1, 1:2, 1:4, 2:1 and 4:1, mol/mol) presented stronger cytotoxicity in SMMC-7721, Bel-7402, HepG-2 and MHCC97H cells, while the combination groups are relatively insensitive to normal hepatocytes (L02). Among them, the molar ratio of 2:1 combination group showed strong synergistic effect in SMMC-7721cells. Then, western blotting assay further verified that the mechanism of the synergistic effect may be related to the inhibition of the expression of NF-κB (overall) and COX-2 protein. In addition, the synergistic effect was also validated in the xenograft mice . This research not only provides a novel and effective combination strategy for the therapy of hepatocellular carcinoma but also provides an experimental basis for the development of CU and 5-FU compound preparation.
姜黄素(CU)已显示出广泛的抗癌作用。5-氟尿嘧啶(5-FU)一直是肝细胞癌的传统化疗药物。不幸的是,长期使用导致的非特异性细胞毒性和多药耐药性限制了5-FU的临床疗效。本研究旨在探讨CU与5-FU联合应用是否能在抑制人肝细胞癌方面产生协同效应。细胞毒性试验结果表明,与单独用药相比,CU与5-FU(1:1、1:2、1:4、2:1和4:1,摩尔/摩尔)联合使用在SMMC-7721、Bel-7402、HepG-2和MHCC97H细胞中表现出更强的细胞毒性,而联合用药组对正常肝细胞(L02)相对不敏感。其中,2:1联合用药组在SMMC-7721细胞中表现出较强的协同效应。然后,蛋白质印迹分析进一步证实,协同效应的机制可能与抑制NF-κB(总体)和COX-2蛋白的表达有关。此外,在异种移植小鼠中也验证了协同效应。本研究不仅为肝细胞癌的治疗提供了一种新颖有效的联合策略,也为CU和5-FU复方制剂的开发提供了实验依据。